ArticleProceedings of the National Academy of Sciences of the United States of America2014
Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03455309 (A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization
Who cites it
54 citing papers in PubMed, 74 citations in OpenAlex.
- Trial
- Conserved CD4Nature microbiology · 2026Article
- From Nature to Nanomedicine: Engineered Plant-Derived Nanovesicles for Skin Disease.International journal of nanomedicine · 2026Review
- A promisingClinical and experimental vaccine research · 2025Review
- Immunogenicity Evaluation of Epitope-Based Vaccine on Target of RNAIII-Activating Protein (TRAP) ofBiology · 2025Article
- Early cytokine signatures and clinical phenotypes discriminate persistent from resolving MRSA bacteremia.BMC infectious diseases · 2025Article
- Review
- Methicillin-resistantCurrent pharmaceutical biotechnology · 2025Review
- IL-10 inhibition during immunization improves vaccine-induced protection against Staphylococcus aureus infection.JCI insight · 2024Article
- Tensor modeling of MRSA bacteremia cytokine and transcriptional patterns reveals coordinated, outcome-associated immunological programs.PNAS nexus · 2024Article
- Impact of interkingdom microbial interactions in the vaginal tract.PLoS pathogens · 2024Article
- Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Th22 is the effector cell of thymosin β15-induced hair regeneration in mice.Inflammation and regeneration · 2024Article
- Promising immunotherapeutic targets for treating candidiasis.Frontiers in cellular and infection microbiology · 2024Review
- Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia.Frontiers in immunology · 2024Article
- Candida-bacterial cross-kingdom interactions.Trends in microbiology · 2023Review
- A CcdB toxin-derived peptide acts as a broad-spectrum antibacterial therapeutic in infected mice.EMBO reports · 2023Article
- The immune evasion roles ofFrontiers in cellular and infection microbiology · 2023Review
- Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin.Microbiology spectrum · 2022Article
- Felodipine enhances aminoglycosides efficacy against implant infections caused by methicillin-resistantBioactive materials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
Increasing rates of life-threatening infections and decreasing susceptibility to antibiotics urge development of an effective vaccine targeting Staphylococcus aureus. This study evaluated the efficacy and immunologic mechanisms of a vaccine containing a recombinant glycoprotein antigen (NDV-3) in mouse skin and skin structure infection (SSSI) due to methicillin-resistant S. aureus (MRSA). Compared with adjuvant alone, NDV-3 reduced abscess progression, severity, and MRSA density in skin, as well as hematogenous dissemination to kidney. NDV-3 induced increases in CD3+ T-cell and neutrophil infiltration and IL-17A, IL-22, and host defense peptide expression in local settings of SSSI abscesses. Vaccine induction of IL-22 was necessary for protective mitigation of cutaneous infection. By comparison, protection against hematogenous dissemination required the induction of IL-17A and IL-22 by NDV-3. These findings demonstrate that NDV-3 protective efficacy against MRSA in SSSI involves a robust and complementary response integrating innate and adaptive immune mechanisms. These results support further evaluation of the NDV-3 vaccine to address disease due to S. aureus in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.